Valuation: Structure Therapeutics Inc.

Market Cap 1.41B 1.28B 1.19B 1.07B 2.02B 133B 2.09B 14.25B 5.65B 71.26B 5.31B 5.2B 226B P/E 2026 *
-8.94x
P/E 2027 * -7.18x
Enterprise Value 738M 669M 619M 558M 1.05B 69.59B 1.09B 7.43B 2.95B 37.17B 2.77B 2.71B 118B EV / Sales 2026 *
-
EV / Sales 2027 * 16,815x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 day+0.81%
1 week-1.72%
Current month-8.55%
1 month-10.35%
3 months-63.44%
6 months-47.48%
Current year-71.24%
1 week 19.07
Extreme 19.07
22.72
1 month 18.7
Extreme 18.7
23.83
Current year 18.7
Extreme 18.7
94.77
1 year 18.7
Extreme 18.7
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 01/05/2022
Chief Executive Officer 62 01/05/2019
Chief Operating Officer 49 15/04/2026
Director TitleAgeSince
Director/Board Member 62 01/02/2019
Chairman 68 19/01/2022
Director/Board Member 66 29/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
21/9/26 Conversion

Chief Technology Officer

-20,040 0.0143%
1/9/26 Exercice

Chief Technology Officer

65,329 0.0467%
18/8/26 Exercice

Chief Technology Officer

43,329 0.0310%
Change 5-day change 1-year change 3-year change Capi.($)
+0.81%-1.72%-42.86%-63.42% 1.41B
-2.69%-5.28%+58.42%+65.89% 68.45B
-0.92%+7.70%+12.90%+93.35% 61.31B
0.00%-0.95%+20.09%+99.04% 55.73B
+0.14%+2.35%+13.08%+109.47% 47.51B
-2.21%-2.47%+18.60%+36.89% 44.68B
-2.30%-10.40%+167.61%+776.79% 38.14B
+2.15%-0.47%+22.85%+56.09% 35.85B
-2.32%-5.14%+75.43%+60.15% 33.05B
+2.62%+5.90%-36.55%+406.95% 25.9B
Average -0.47%+2.57%+30.96%+164.12% 41B
Weighted average by Cap. -0.85%+2.25%+38.98%+161.83%

Financials

2026 *2027 *
Net sales - 55.56K 50.35K 46.57K 42.02K 79.18K 5.24M 81.97K 559K 222K 2.8M 209K 204K 8.88M
Net income -482M -437M -404M -365M -687M -45.46B -711M -4.86B -1.93B -24.29B -1.81B -1.77B -77.09B -591M -536M -496M -447M -843M -55.76B -873M -5.95B -2.36B -29.79B -2.22B -2.17B -94.55B
Net Debt -677M -613M -567M -512M -965M -63.81B -999M -6.81B -2.7B -34.09B -2.54B -2.49B -108B -481M -435M -403M -363M -685M -45.31B -709M -4.84B -1.92B -24.2B -1.8B -1.77B -76.83B
Projected Income Statement - Annual - Structure Therapeutics Inc.
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
281
Date Price Change Volume
14/11/26 US$20.00 +0.81% 1,345,855
12/11/26 US$19.84 -5.30% 1,038,141
11/11/26 US$20.95 -3.59% 1,002,761
10/11/26 US$21.73 +1.49% 1,443,834
09/11/26 US$21.41 +5.21% 1,235,658
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Structure Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
19.84USD
Average target price
104.86USD
Spread / Average Target
+428.51%
  1. Stock Market
  2. Stocks
  3. GPCR Stock